{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:06:52Z","timestamp":1781737612314,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40265-024-02012-9","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T03:02:11Z","timestamp":1709002931000},"page":"363-368","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Berdazimer Topical Gel, 10.3%: First Approval"],"prefix":"10.1007","volume":"84","author":[{"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"issue":"11","key":"2012_CR1","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.36849\/JDD.6383","volume":"20","author":"L Eichenfield","year":"2021","unstructured":"Eichenfield L, Hebert A, Mancini A, et al. Therapeutic approaches and special considerations for treating molluscum contagiosum. J Drugs Dermatol. 2021;20(11):1185\u201390.","journal-title":"J Drugs Dermatol"},{"issue":"12","key":"2012_CR2","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1007\/s13555-022-00826-7","volume":"12","author":"F Lacarrubba","year":"2022","unstructured":"Lacarrubba F, Micali G, Trecarichi AC, et al. New developing treatments for molluscum contagiosum. Dermatol Ther (Heidelb). 2022;12(12):2669\u201378.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"2","key":"2012_CR3","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S1473-3099(14)71053-9","volume":"15","author":"JR Olsen","year":"2015","unstructured":"Olsen JR, Gallacher J, Finlay AY, et al. Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study. Lancet Infect Dis. 2015;15(2):190\u20135.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"2012_CR4","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2022.2719","volume":"158","author":"VS Oza","year":"2022","unstructured":"Oza VS. Molluscum contagiosum therapeutics\u2014new options may be around the corner. JAMA Dermatol. 2022;158(8):863\u20134.","journal-title":"JAMA Dermatol"},{"key":"2012_CR5","unstructured":"US Food & Drug Administration. FDA approves first treatment for molluscum contagiosum [media release]. 24 Jul 2023. https:\/\/www.fda.gov\/."},{"issue":"00","key":"2012_CR6","first-page":"1","volume":"00","author":"JL Sugarman","year":"2023","unstructured":"Sugarman JL, Hebert A, Browning JC, et al. Berdazimer gel for molluscum contagiosum: an integrated analysis of 3 randomized controlled trials. J Am Acad Dermatol. 2023;00(00):1\u201310.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2012_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.xjidi.2021.100019","volume":"1","author":"T Maeda-Chubachi","year":"2021","unstructured":"Maeda-Chubachi T, Hebert D, Messersmith E, Siegfried EC. SB206, a nitric oxide-releasing topical medication, induces the beginning of the end sign and molluscum clearance. JID Innov. 2021;1(3):1\u20138.","journal-title":"JID Innov."},{"issue":"1 Suppl","key":"2012_CR8","first-page":"s4","volume":"16","author":"JQ Del Rosso","year":"2017","unstructured":"Del Rosso JQ, Kircik J. Spotlight on the use of nitric oxide in dermatology: What is it? What does it do? Can it become an important addition to the therapeutic armamentarium for skin disease? J Drugs Dermatol. 2017;16(1 Suppl):s4\u201310.","journal-title":"J Drugs Dermatol."},{"issue":"00","key":"2012_CR9","first-page":"1","volume":"170","author":"NS Banerjee","year":"2019","unstructured":"Banerjee NS, Moore DW, Wang HK, et al. NVN1000, a novel nitric oxide-releasing compound, inhibits HPV-18 virus production by interfering with E6 and E7 oncoprotein functions. Antiviral Res. 2019;170(00):1\u20139.","journal-title":"Antiviral Res"},{"issue":"10","key":"2012_CR10","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.36849\/JDD.6938","volume":"21","author":"M Cartwright","year":"2022","unstructured":"Cartwright M, Enloe C, Stripling S, Maeda-Chubachi T. Pharmacokinetic profile, safety, and tolerability of topical berdazimer gel, 10.3% in patients with molluscum contagiosum. J Drugs Dermatol. 2022;21(10):1104\u201310.","journal-title":"J Drugs Dermatol"},{"key":"2012_CR11","unstructured":"Novan Inc. Our Science: NITRICILTM. 2024. https:\/\/novan.com\/our-science\/. Accessed 31 Jan 2024."},{"key":"2012_CR12","unstructured":"LNHC Inc. ZELSUVMI\u2122 (berdazimer topical gel, 10.3%): US prescribing information. 2024. https:\/\/zelsuvmi.com\/. Accessed Jan 9, 2024"},{"key":"2012_CR13","unstructured":"Sato Pharmaceutical Co Ltd. Open-label study to evaluate the safety and tolerability of SB206 in Japanese patients with molluscum contagiosum. 2020. https:\/\/jrct.niph.go.jp\/latest-detail\/jRCT2031230123. Accessed 30 Jan 2024."},{"key":"2012_CR14","unstructured":"Ligand Pharmaceuticals Inc. Ligand acquires assets of Novan, Inc. for $12.2 million [media release]. 27 Sep 2023. https:\/\/investor.ligand.com\/."},{"key":"2012_CR15","unstructured":"Ligand Pharmaceuticals Inc. Ligand acquires milestone and royalty rights to SB206 from Novan, Inc [media release]. 6 May 2019. https:\/\/investor.ligand.com\/."},{"key":"2012_CR16","unstructured":"Novan Inc. Novan expands nitric oxide dermatology business partnership with Sato in Japan [media release]. 8 Oct 2018. https:\/\/www.novan.com\/."},{"issue":"8","key":"2012_CR17","first-page":"871","volume":"158","author":"JC Browning","year":"2022","unstructured":"Browning JC, Enloe C, Cartwright M, et al. Efficacy and safety of topical nitric oxide-releasing berdazimer gel in patients with molluscum contagiosum: a phase 3 randomized clinical trial. JAMA Dermatol. 2022;158(8):871\u20138.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"2012_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v15122360","volume":"15","author":"BM Ward","year":"2023","unstructured":"Ward BM, Riccio DA, Cartwright M, Maeda-Chubachi T. The antiviral effect of berdazimer sodium on molluscum contagiosum virus using a novel in vitro methodology. Viruses. 2023;15(12):1\u201311.","journal-title":"Viruses"},{"key":"2012_CR19","unstructured":"Stripling S, Hebert A, Enloe C, et al. Clinical development program of novel topical nitric oxide releasing medication berdazimer gel 10.3% for the once-daily treatment of molluscum contagiosum [abstract no. and poster]. In: SCALE 2022. 2022."},{"key":"2012_CR20","unstructured":"Novan Inc. A phase 3 efficacy & safety of SB206 & vehicle gel for the treatment of MC (B-SIMPLE2). 2022. https:\/\/clinicaltrials.gov\/. Accessed 1 Feb 2024."},{"key":"2012_CR21","unstructured":"Novan Inc. A phase 3 randomized parallel group study comparing the efficacy & safety of SB206 & vehicle gel in the treatment of MC (B-SIMPLE1). 2022. https:\/\/clinicaltrials.gov\/. Accessed 1 Feb 2024."},{"issue":"4","key":"2012_CR22","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.jaad.2019.09.064","volume":"82","author":"AA Hebert","year":"2020","unstructured":"Hebert AA, Siegfried EC, Durham T, et al. Efficacy and tolerability of an investigational nitric oxide-releasing topical gel in patients with molluscum contagiosum: a randomized clinical trial. J Am Acad Dermatol. 2020;82(4):887\u201394.","journal-title":"J Am Acad Dermatol"},{"key":"2012_CR23","unstructured":"Ligand Pharmaceuticals Inc. U.S. Food and Drug Administration approves ZELSUVMI\u2122 as a first-in-class medication for the treatment of molluscum contagiosum [media release]. 5 Jan 2024. https:\/\/investor.ligand.com\/."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02012-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02012-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02012-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T18:06:39Z","timestamp":1711908399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02012-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2012"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02012-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,27]]},"assertion":[{"value":"27 February 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}